Skip to main content
Erschienen in: Clinical Pharmacokinetics 11/2001

01.11.2001 | Leading Article

Individualising Aminoglycoside Dosage Regimens after Therapeutic Drug Monitoring

Simple or Complex Pharmacokinetic Methods?

verfasst von: Michel M. Tod, Christophe Padoin, Olivier Petitjean

Erschienen in: Clinical Pharmacokinetics | Ausgabe 11/2001

Einloggen, um Zugang zu erhalten

Abstract

Measurements of aminoglycoside concentration in serum are used to individualise dosage regimens (dose per administration and/or administration interval) with the goal of attaining the desired therapeutic range as quickly as possible. Therapeutic range is defined in terms of peak concentration (to monitor effectiveness) and trough concentration (to avoid toxicity). This article focuses on methods to individualise aminoglycoside dosage regimens in the context of extended dosage intervals.
Simple pharmacokinetic methods involve linear dosage adjustment based on peak or trough concentrations or area under the concentration-time curve, or nomograms. The once daily aminoglycoside nomogram determines the dosage interval for aminoglycosides given as a fixed dose per administration, based on a single concentration measurement drawn 6 to 14 hours after the start of the first infusion. This is a preferred method because of its simplicity, strong pharmacodynamic rationale and prospective validation in a large population. However, it does not work when the fixed dose assumed is not relevant, for example for patients with burns, cystic fibrosis, ascites or pregnancy. Furthermore, it has not been validated in children. In these cases, a more sophisticated method is required.
Complex pharmacokinetic methods require dedicated software. Non-Bayesian least-squares methods allow the optimisation of both the dose and the dosage interval, but require aminoglycoside concentrations from two or more samples taken in the post-distributive phase during a single dosage interval. With Bayesian least-squares methods, only one concentration measurement is required, although any number of samples can be taken into account. In the Bayesian maximum a posteriori (MAP) method, the parameter estimates are taken as the values corresponding to the maximum of the posterior density. In ‘full’ Bayesian approaches (also called stochastic control), all the information about the parameters revealed by the posterior distribution is taken into account, and the optimal regimen is found by minimising the expected value of the weighted sum of squared deviations between predicted and target concentrations.
If the population model is reasonably well known, Bayesian methods (MAP or stochastic control) should be used because of their good predictive performance. Although only one concentration measurement is required, better precision is afforded by a two-sample strategy, preferably drawn 1 and 6 hours after the start of the first infusion. If the population model is not known, then the non-Bayesian least-squares method is the method of choice, because of its robustness and lack of requirement for prior information about the distribution of parameters in the population.
Literatur
1.
Zurück zum Zitat Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407–11PubMedCrossRef Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407–11PubMedCrossRef
2.
Zurück zum Zitat Zaske DE, Irvine P, Strand LM, et al. Wide interpatient variations in gentamicin dose requirements for geriatric patients. JAMA 1982; 248: 3122–6PubMedCrossRef Zaske DE, Irvine P, Strand LM, et al. Wide interpatient variations in gentamicin dose requirements for geriatric patients. JAMA 1982; 248: 3122–6PubMedCrossRef
3.
Zurück zum Zitat Rodvold KA, Zokufa H, Rotschafer JC. Aminoglycoside pharmacokinetic monitoring: an integral part of patient care? Clin Pharm 1988; 7: 608–13PubMed Rodvold KA, Zokufa H, Rotschafer JC. Aminoglycoside pharmacokinetic monitoring: an integral part of patient care? Clin Pharm 1988; 7: 608–13PubMed
4.
Zurück zum Zitat Lacy MK, Nicolau DP. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23–7PubMedCrossRef Lacy MK, Nicolau DP. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23–7PubMedCrossRef
5.
Zurück zum Zitat McCormack JP, Jeweson PJ. A critical reevaluation of the ‘therapeutic range’ of aminoglycosides. Clin Infect Dis 1992; 14: 320–39PubMedCrossRef McCormack JP, Jeweson PJ. A critical reevaluation of the ‘therapeutic range’ of aminoglycosides. Clin Infect Dis 1992; 14: 320–39PubMedCrossRef
6.
Zurück zum Zitat Burton ME, Ash CL, Hill DP, et al. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49: 685–94PubMedCrossRef Burton ME, Ash CL, Hill DP, et al. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49: 685–94PubMedCrossRef
7.
Zurück zum Zitat Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5PubMedCrossRef Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5PubMedCrossRef
8.
Zurück zum Zitat Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity [abstract A79]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity [abstract A79]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego
9.
Zurück zum Zitat Anaizi N. Once-daily dosing of aminoglycosides: a consensus document. Int J Clin Pharmacol Ther 1997; 35: 223–6PubMed Anaizi N. Once-daily dosing of aminoglycosides: a consensus document. Int J Clin Pharmacol Ther 1997; 35: 223–6PubMed
10.
Zurück zum Zitat Morris RG, Sallustio BC, Vinks AT, et al. Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther Drug Monit 1999; 21: 379–88PubMedCrossRef Morris RG, Sallustio BC, Vinks AT, et al. Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther Drug Monit 1999; 21: 379–88PubMedCrossRef
11.
Zurück zum Zitat Bertino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994; 26: 71–81PubMedCrossRef Bertino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994; 26: 71–81PubMedCrossRef
12.
Zurück zum Zitat Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effects of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549–55PubMed Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effects of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549–55PubMed
13.
Zurück zum Zitat Barclay ML, Kirckpatrick CMJ, Begg EJ. Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89–98PubMedCrossRef Barclay ML, Kirckpatrick CMJ, Begg EJ. Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89–98PubMedCrossRef
14.
Zurück zum Zitat Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacokinetics of isepamicin. Clin Pharmacokinet 2000; 38: 205–23PubMedCrossRef Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacokinetics of isepamicin. Clin Pharmacokinet 2000; 38: 205–23PubMedCrossRef
15.
Zurück zum Zitat Dager WE. Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother 1994; 28: 944–51PubMed Dager WE. Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother 1994; 28: 944–51PubMed
16.
Zurück zum Zitat Dasta JF, Armstrong DB. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327–30PubMedCrossRef Dasta JF, Armstrong DB. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327–30PubMedCrossRef
17.
Zurück zum Zitat Marick PA. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172–3 Marick PA. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172–3
18.
Zurück zum Zitat Reed RL, Ericsson CD, Wu A, et al. The pharmacokinetics of prophylactic antibiotics in trauma. J Trauma 1992; 32: 21–7PubMedCrossRef Reed RL, Ericsson CD, Wu A, et al. The pharmacokinetics of prophylactic antibiotics in trauma. J Trauma 1992; 32: 21–7PubMedCrossRef
19.
Zurück zum Zitat Prins JM, Weverling GJ, de Blok K, et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996; 40: 2494–9PubMed Prins JM, Weverling GJ, de Blok K, et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996; 40: 2494–9PubMed
20.
Zurück zum Zitat Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9PubMedCrossRef Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9PubMedCrossRef
21.
Zurück zum Zitat Xiong YQ, Caillon J, Kergueris MF, et al. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997; 41: 823–6PubMed Xiong YQ, Caillon J, Kergueris MF, et al. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997; 41: 823–6PubMed
22.
Zurück zum Zitat Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143–60PubMedCrossRef Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143–60PubMedCrossRef
23.
Zurück zum Zitat Barclay ML, Duffull SB, Begg EJ, et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 1995; 25: 230–5PubMedCrossRef Barclay ML, Duffull SB, Begg EJ, et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 1995; 25: 230–5PubMedCrossRef
24.
Zurück zum Zitat El Bakri F, Pallett A, Smith AG, et al. Ototoxicity induced by once-daily gentamicin. Lancet 1998; 351: 1407–8PubMedCrossRef El Bakri F, Pallett A, Smith AG, et al. Ototoxicity induced by once-daily gentamicin. Lancet 1998; 351: 1407–8PubMedCrossRef
25.
Zurück zum Zitat Tod M, Minozzi C, Beaucaire G, et al. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother 1999; 44: 99–108PubMedCrossRef Tod M, Minozzi C, Beaucaire G, et al. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother 1999; 44: 99–108PubMedCrossRef
26.
Zurück zum Zitat Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445–52PubMedCrossRef Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445–52PubMedCrossRef
27.
Zurück zum Zitat Zeitany RG, el Saghir NS, Santosh-Kumar CR, et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34: 702–8PubMedCrossRef Zeitany RG, el Saghir NS, Santosh-Kumar CR, et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990; 34: 702–8PubMedCrossRef
29.
Zurück zum Zitat Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet Biopharm 1976; 4: 183–95 Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet Biopharm 1976; 4: 183–95
30.
Zurück zum Zitat Buffington DE, Lampasona V, Chandler HH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205–16PubMedCrossRef Buffington DE, Lampasona V, Chandler HH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205–16PubMedCrossRef
31.
Zurück zum Zitat Jelliffe RW, Iglesias T, Hurst AK, et al. Individualising gentamicin dosage regimens: a comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991; 21: 461–78PubMedCrossRef Jelliffe RW, Iglesias T, Hurst AK, et al. Individualising gentamicin dosage regimens: a comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991; 21: 461–78PubMedCrossRef
32.
Zurück zum Zitat Kosirog JL, Rospond RM, Destache C, et al. Aminoglycoside forecasting in neutropenic patients with cancer. Clin Pharmacokinet 1993; 24: 79–87PubMedCrossRef Kosirog JL, Rospond RM, Destache C, et al. Aminoglycoside forecasting in neutropenic patients with cancer. Clin Pharmacokinet 1993; 24: 79–87PubMedCrossRef
33.
Zurück zum Zitat Lui K, Bryson SM, Irwin DB, et al. Evaluation of Bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less. Am J Dis Child 1991; 145: 463–7PubMed Lui K, Bryson SM, Irwin DB, et al. Evaluation of Bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less. Am J Dis Child 1991; 145: 463–7PubMed
34.
Zurück zum Zitat McClellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates. Ther Drug Monit 1989; 11: 431–6PubMed McClellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates. Ther Drug Monit 1989; 11: 431–6PubMed
35.
Zurück zum Zitat Katz D, d’Argenio DZ. Implementation and evaluation of control strategies for individualizing dosage regimens, with application to aminoglycoside antibiotics. J Pharmacokinet Biopharm 1986; 14: 523–37PubMed Katz D, d’Argenio DZ. Implementation and evaluation of control strategies for individualizing dosage regimens, with application to aminoglycoside antibiotics. J Pharmacokinet Biopharm 1986; 14: 523–37PubMed
36.
Zurück zum Zitat Jelliffe RW, Bayard D, Milman M, et al. Achieving target goals most precisely using non parametric compartmental models and multiple model design of dosage regimens. Ther Drug Monit 2000; 22: 346–53PubMedCrossRef Jelliffe RW, Bayard D, Milman M, et al. Achieving target goals most precisely using non parametric compartmental models and multiple model design of dosage regimens. Ther Drug Monit 2000; 22: 346–53PubMedCrossRef
37.
Zurück zum Zitat Tod M, Alet P, Lortholary O, et al. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen. J Pharmacokinet Biopharm; 1997; 25: 695–712PubMed Tod M, Alet P, Lortholary O, et al. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen. J Pharmacokinet Biopharm; 1997; 25: 695–712PubMed
38.
Zurück zum Zitat Erb RJ. The back propagation neural network — a Bayesian classifier: introduction and applicability to pharmacokinetics. Clin Pharmacokinet 1995; 29: 69–79PubMedCrossRef Erb RJ. The back propagation neural network — a Bayesian classifier: introduction and applicability to pharmacokinetics. Clin Pharmacokinet 1995; 29: 69–79PubMedCrossRef
39.
Zurück zum Zitat Brier ME, Furada JM, Aronoff GR. Neural network predicted peak and trough gentamicin concentrations. Pharm Res 1995; 12: 406–12PubMedCrossRef Brier ME, Furada JM, Aronoff GR. Neural network predicted peak and trough gentamicin concentrations. Pharm Res 1995; 12: 406–12PubMedCrossRef
40.
Zurück zum Zitat Jelliffe RW, Schumitzky A, Van Guilder M. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision: a simulation study. Drug Invest 1992; 4: 20–9CrossRef Jelliffe RW, Schumitzky A, Van Guilder M. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision: a simulation study. Drug Invest 1992; 4: 20–9CrossRef
41.
Zurück zum Zitat Vozeh S, Steiner C. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis. J Pharmacokinet Biopharm 1987; 15: 511–28PubMed Vozeh S, Steiner C. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis. J Pharmacokinet Biopharm 1987; 15: 511–28PubMed
42.
Zurück zum Zitat Tanigawara Y, Yano I, Kawakatsu K, et al. Predictive performance of the Bayesian analysis: effect of blood sampling time, population parameters and pharmacostatistical model. J Pharmacokinet Biopharm 1994; 22: 59–71PubMed Tanigawara Y, Yano I, Kawakatsu K, et al. Predictive performance of the Bayesian analysis: effect of blood sampling time, population parameters and pharmacostatistical model. J Pharmacokinet Biopharm 1994; 22: 59–71PubMed
43.
Zurück zum Zitat Keller F, Erdmann K, Giehl M, et al. Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin. Clin Pharmacokinet 1993; 25: 71–9PubMedCrossRef Keller F, Erdmann K, Giehl M, et al. Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin. Clin Pharmacokinet 1993; 25: 71–9PubMedCrossRef
44.
Zurück zum Zitat Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med 1987; 82: 945–52PubMedCrossRef Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med 1987; 82: 945–52PubMedCrossRef
45.
Zurück zum Zitat Mohler JL, Barton SD, Blouin RA, et al. The evaluation of creatinine clearance in spinal cord injury patients. J Urol 1986; 136: 366–9PubMed Mohler JL, Barton SD, Blouin RA, et al. The evaluation of creatinine clearance in spinal cord injury patients. J Urol 1986; 136: 366–9PubMed
46.
Zurück zum Zitat Best NG, Spiegelhalter DJ, Thomas A, et al. Bayesian analysis of realistically complex models. J Royal Statist Soc A 1996; 159: 323–42CrossRef Best NG, Spiegelhalter DJ, Thomas A, et al. Bayesian analysis of realistically complex models. J Royal Statist Soc A 1996; 159: 323–42CrossRef
47.
Zurück zum Zitat Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides: antimicrobial therapy — II. Med Clin North Am 1995; 79: 761–87PubMed Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides: antimicrobial therapy — II. Med Clin North Am 1995; 79: 761–87PubMed
48.
Zurück zum Zitat Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761–5PubMed Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761–5PubMed
49.
Zurück zum Zitat Touw DJ, Jacobs FAH, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 184–7PubMed Touw DJ, Jacobs FAH, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 184–7PubMed
Metadaten
Titel
Individualising Aminoglycoside Dosage Regimens after Therapeutic Drug Monitoring
Simple or Complex Pharmacokinetic Methods?
verfasst von
Michel M. Tod
Christophe Padoin
Olivier Petitjean
Publikationsdatum
01.11.2001
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 11/2001
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200140110-00002

Weitere Artikel der Ausgabe 11/2001

Clinical Pharmacokinetics 11/2001 Zur Ausgabe

Current Opinion

Pharmacogenetics